Clinical Insights in Geriatrics: Setting the Stage: Stage-Specific Treatment Options for Patients With Moderate to Severe Alzheimer’s Disease
Release Date: December-16-11
Credit Expiration Date: September-16-13
Senior care providers including primary care physicians, long-term care physicians, nurses, consultant pharmacists, and others interested in the care of older patients with Alzheimer's disease.
Family Physicians: 0.5 Prescribed credit
Nurses: 0.5 Contact Hours
Pharmacists: 0.5 Contact Hour (0.05 CEU)
As the US population ages, dementia syndromes such as Alzheimer’s disease (AD) are growing more prevalent. Roughly 60% to 80% of elderly patients with chronic dementia have AD, a progressive condition that leads to memory loss, personality changes, cognitive dysfunction, and functional impairment. The Practice Guidelines for the Treatment of Patients With Alzheimer’s Disease and Other Dementias, 2nd Edition (2007) and other related guidelines stress the importance of individualized and multimodal treatment plans. Recognizing symptomatology of AD at its various stages can help providers select appropriate therapies.
Continuing education is required to help primary care providers and other senior care clinicians ensure that patients are being evaluated and treated properly. Patients with dementia need to be stratified based on the severity of their disease and treated accordingly, but many providers do not know how long to treat AD since there is no established standard on the duration of treatment.
David S. Geldmacher, MD, FACP
Charles and Patsy Collat Professor of Neurology
Director, Division of Memory Disorders and Behavioral Neurology
University of Alabama – Birmingham
Lori A. Daiello, PharmD, BCPP
Assistant Professor of Neurology (Research)
Warren Alpert Medical School
Elizabeth M. Galik, PhD, CRNP
University of Maryland School of Nursing
Mary Campagnolo, MD, MBA, FAAFP, DABFM, CAQ-Geriatrics
Virtua-Lumberton Family Physicians
It is the policy of the AAFP, ASCP, and NADONA to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Dr. Geldmacher discloses the following: Consultant: Bayer, Eisai, Glaxo, Janssen; Grant/Research Support: Baxter, BMS, Janssen, Novartis, Pfizer.
Dr. Diaello discloses the following: Consultant: Eli Lilly.
Dr. Galnik discloses the following: Consultant: Novartis.
Dr. Campangola has no relevant financial conflicts to disclose.
Ms. Dechevalier has no relevant financial conflicts to disclose.
Dr. Gerber has no relevant financial conflicts to disclose.
Ms. Barrett has no relevant financial conflicts to disclose.
Ms. Dornberger has no relevant financial conflicts to disclose.
Dr. Thier has no relevant financial conflicts to disclose.
Dr. Paczolt has no relevant financial conflicts to disclose.
Dr. Lee has no relevant financial conflicts to disclose.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This Enduring Material activity, Clinical Insights in Geriatrics: Setting the Stage: Stage-Specific Treatment Options for Patients With Moderate to Severe Alzheimer’s Disease, has been reviewed and is acceptable for up to 0.50 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins December 15, 2011. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity #0203-9999-11-163-H01-P, has been assigned 0.5 Contact Hour (0.05 CEU).
NADONA/LTC is an approved provider of continuing nursing education by Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation #1088. This activity provides 0.5 contact hour by NADONA/LTC.
Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit. Credit will be awarded for a score of 80% or better, and a statement may be printed immediately after passing the post-test.
There is no fee to participate in this educational activity.
This activity is supported by an educational grant from Pfizer Inc.
© 2011, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, ASCP, NJAFP, NADONA, or Pfizer Inc. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.